Press Releases
Our press releases
- Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients Aug 24 2021
- Bio-Path Holdings Reports Second Quarter 2021 Financial Results Aug 13 2021
- Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021 Aug 6 2021
- Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003 Jun 22 2021
- Bio-Path Holdings Reports First Quarter 2021 Financial Results May 14 2021
- Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021 May 7 2021
- Bio-Path Announces Publication in Biomedicines Apr 22 2021
- Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting Apr 12 2021
- Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia Apr 5 2021
- Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting Mar 11 2021
Show More Posts
Loading...